Cellectis (CLLS)

• Market cap: $417M
• 1 day: 4.27%
• 5 days: 3.23%
• 1 month: 1.72%
• 3 months: -20.8%
• 6 months: 54.28%
• Year to date: -13.54%
• 1 year: 198.56%
• 5 years: -79.89%
• 10 years: -80.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222